

1962

1989

-

- -

2015 -

2016

2018

2022

2024

2019

2020

NUCLEAR MEDICINE **BEGINS AT OHSU** Approximate start of Nuclear Medicine at OHSU, within the Department of Pathology. I-131 therapies are being done at this time.

NUCLEAR MEDICINE JOINS **DIAGNOSTIC RADIOLOGY** Dr. Jeffrey Stevens is appointed the new Section Chief.

PET/CT CAMERA INSTALLED FDG PET scans start.

XOFIGO THERAPY BEGINS Approximate date of first therapy.

DOTATATE AND AXUMIN PET BEGIN Start of NET and prostate PET.

LAUNCH OF THERANOSTICS PROGRAM Dr. Erik Mittra appointed as Section Chief and Lutathera therapies start.

SECTION NAME CHANGES Nuclear Medicine changes to Molecular Imaging and Therapy.

NUCLEAR MEDICINE ADDS SOUTH WATERFRONT LOCATION Two SPECT/CTs installed as part of a larger imaging expansion

FIRST PET/MR CAMERA INSTALLED First in the Pacific Northwest. PSMA PET also begins.

project at CHH.

PLUVICTO THERAPY BEGINS

NEW CLINIC OPENS

Molecular Imaging and Therapy moves to new state-of-the-art clinic space in Hatfield Research Center. Amyloid brain PET and cardiac perfusion PET begin.

Our Team

Section Chief

Erik Mittra, M.D., Ph.D.

Faculty

Gagandeep Choudhary, M.D. Nadine Mallak, M.D.

Sebastian Obrzut, M.D.
Laszlo Szidonya, M.D., PhD.

Advanced Practice Provider

Katie Barnett, D.N.P.

Supervisor

Mike Nguyen

Technologists

Ryan Anderson Hollie Hendricks Joseph Andrulewicz Elvse Mace Ezra Phillip Morse Kyndall Cooney Lindsey Durden Talon Ray Jordan Emerson Matthew Riggins Derrick Gillan Victoria West Amy Harker Heather Whalon **Registered Nurses** Peggy Elia Jason Dictson

Jenny Lee Bree Murphy Derek Penfield

Administrative Coordinator

Melissa Reed

Physics

Liz Henry

Caffi Meyer, Ph.D. Tom Griglock, Ph.D. Celeste Winters, Ph.D. Anna Mench, Ph.D. Research Libby Mirande Lauren Drake Clayton Ridner Trent Ethridge Casie Goldman

Technologist Extern Students

Rachel Hugulet

Lupe Urbano

Mark O. Hatfield Research Center 3250 S.W. Sam Jackson Park Rd. Portland, OR 97239 ohsu.edu/mitclinic

MOLECULAR IMAGING AND THERAPY

Theranostics Program






OHSU

Theranostics Program

Nuclear Medicine originated with the first Iodine-131 therapy over 77 years ago and is now experiencing a resurgence with several new FDA-approved radiopharmaceuticals for imaging and therapy and many more in clinical trials, resulting in the burgeoning field of theranostics. The OHSU Theranostics Program launched in 2018.

THERAPY VOLUME

There has been a 621% therapy volume growth over the past six years, driven by these new therapies.




What is Theranostics?

Theranostics combines the words "therapy" and "diagnostics", emphasizing the fusion of these approaches within one technology. The goal of theranostics is to personalize and thereby optimize medical treatment by tailoring it to the individual characteristics of a patient, often based on molecular information. While a general term in medicine, the clearest and most common example is in Molecular Imaging and Therapy.

What is Molecular Imaging and Therapy?

Molecular Imaging and Therapy (MIT, also called Nuclear Medicine) is a medical subspecialty that uses small amounts of radioactive isotopes to image and treat various diseases and conditions. The targeted radioactivity is administered internally and the emitted radiation is used to either create images (gamma and PET scans) or treat disease.

COMBINED MIT IMAGING AND THERAPY VOLUME



This section has seen a 47% growth over the past six years.




Illustration by Dennis Barbon, M.D.

These are the three main types of radiation used in MIT. Each interacts with tissue differently. As such, alpha particles can only be used for therapy, gamma rays are only used for imaging, and beta particles can be used for imaging or therapy.





Figure by Caffi Meyer, Ph.D.

The power of theranostics is shown. Everything in red is metastatic disease which is visualized using PET imaging, while the improvement is a result of the therapy, both targeting the same receptor on the cancer cell.



Based on the theranostics principle, OHSU MIT provides advanced patient specific dosimetry to help optimize the dose and further improve patient outcomes to the therapy.